GENE ONLINE|News &
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
In a flurry of highs and lows for Biogen this week, the company voluntarily paid a $900 million settlement in a lawsuit brought about by a former employee regarding alleged paid kickbacks for physicians willing to prescribe the company’s multiple sclerosis drugs. At the other end of Biogen’s week, the company reported positive Phase 3 confirmatory trial results from its newest Alzheimer’s drug developed with Eisai, lecanemab, which is set for a regulatory decision in January next year.
